The effectiveness of anticoagulant therapy in Covid-19 associated ischemic stroke

32 patients with acute ischemic stroke and a history of coronavirus infection (not more than 2 months) were selected for the study. These patients (n = 32) were divided into three groups. In the first group, n = 17 (53.1%) patients received heparin as anticoagulant therapy for 2 weeks at 24000-36000 ED per day, n = 9 (28.1%) patients in the second group received enoxiparin 1 mg /kg /day for 2 weeks, and third group consisted of n = 6 (18.8%) patients received rivaroxaban 15-20 mg per day for 2 weeks. Hemorheological parameters (D-demir, INR, fibrinogen, prothrombin time, APTT) of all patients were checked before and 2 weeks after therapy.

Ҳали таржима қилинмаган